Quadrant Capital Group LLC Acquires 1,030 Shares of Genmab A/S (NASDAQ:GMAB)

Quadrant Capital Group LLC increased its holdings in Genmab A/S (NASDAQ:GMAB) by 16.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,274 shares of the company’s stock after buying an additional 1,030 shares during the period. Quadrant Capital Group LLC’s holdings in Genmab A/S were worth $276,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. First Manhattan Co. bought a new position in Genmab A/S in the fourth quarter worth approximately $26,000. Parallel Advisors LLC raised its stake in Genmab A/S by 54.8% in the second quarter. Parallel Advisors LLC now owns 1,158 shares of the company’s stock worth $44,000 after buying an additional 410 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in Genmab A/S by 69.0% in the first quarter. Great West Life Assurance Co. Can now owns 1,590 shares of the company’s stock worth $60,000 after buying an additional 649 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Genmab A/S by 62.0% during the first quarter. Captrust Financial Advisors now owns 2,658 shares of the company’s stock worth $96,000 after purchasing an additional 1,017 shares in the last quarter. Finally, Atlas Capital Advisors LLC increased its position in shares of Genmab A/S by 176.4% during the fourth quarter. Atlas Capital Advisors LLC now owns 2,488 shares of the company’s stock worth $105,000 after purchasing an additional 1,588 shares in the last quarter. Institutional investors own 6.29% of the company’s stock.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $32.80 on Friday. Genmab A/S has a one year low of $27.74 and a one year high of $47.50. The firm has a market cap of $21.67 billion, a price-to-earnings ratio of 34.89, a PEG ratio of 2.11 and a beta of 1.00. The firm’s fifty day moving average is $32.95 and its two-hundred day moving average is $36.92.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. BTIG Research upped their price target on Genmab A/S from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, October 13th. Nordea Equity Research downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research report on Monday, July 31st. HC Wainwright reduced their price target on Genmab A/S from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, November 7th. Finally, BNP Paribas began coverage on shares of Genmab A/S in a report on Wednesday, October 18th. They set an “underperform” rating on the stock. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $757.00.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.